Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes

Cell Calcium

Volumn 55, Issue 2, 2014, Pages 104-118

  Al Kury, Lina T ^a   Voitychuk, Oleg I ^b   Ali, Ramiz M ^a   Galadari, Sehamuddin ^a   Yang, Keun Hang Susan ^c   Howarth, Frank Christopher ^a   Shuba, Yaroslav M ^b   Oz, Murat ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^c CHAPMAN UNIVERSITY   (United States)

Author keywords

Anandamide; Contraction; Endocannabinoid; Intracellular calcium; Ventricular action potential; Ventricular myocytes

Indexed keywords

ANANDAMIDE; RYANODINE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EVOKED MUSCLE RESPONSE; EXCITATION CONTRACTION COUPLING; FLUORESCENCE ANALYSIS; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; INOTROPISM; MALE; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; WHOLE CELL PATCH CLAMP;

RATTUS;

ANANDAMIDE; CONTRACTION; ENDOCANNABINOID; INTRACELLULAR CALCIUM; VENTRICULAR ACTION POTENTIAL; VENTRICULAR MYOCYTES;

ACTION POTENTIALS; ANIMALS; ARACHIDONIC ACIDS; CAFFEINE; CALCIUM; CALCIUM SIGNALING; ENDOCANNABINOIDS; FURA-2; HEART VENTRICLES; INDOLES; MALE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PERTUSSIS TOXIN; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SARCOPLASMIC RETICULUM; TRANSPORT VESICLES;

EID: 84893953431     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2013.12.005     Document Type: Article

References (63)

1. Di Marzo V., De Petrocellis L., Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb. Exp. Pharmacol. 2005, 168:147-185.
2. Hanus L.O., Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr. Med. Chem. 2010, 17:1341-1359.
3. Pertwee R.G., Howlett A.C., Abood M.E., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol. Rev. 2010, 62:588-631.
4. Batkai S., Pacher P. Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol. Res. 2009, 60:99-106.
5. Montecucco F., Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol. Sci. 2012, 33:331-340.
6. Malinowska B., Baranowska-Kuczko M., Schlicker E. Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?. Br. J. Pharmacol. 2012, 165:2073-2088.
7. Randall M.D., Kendall D.A., O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. 2004, 142:20-26.
8. Mendizabal V.E., Dler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br. J. Pharmacol. 2007, 151:427-440.
9. Ford W.R., Honan S.A., White R., Hiley C.R. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol. 2002, 135:1191-1198.
10. Bonz A., Laser M., Kullmer S., et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. 2003, 41:657-664.
11. Sterin-Borda L., Del Zar C.F., Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem. Pharmacol. 2005, 69:1705-1713.
12. Su Z., Preusser L., Diaz G., et al. Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors. Curr. Drug Saf. 2011, 6:277-284.
13. 2+ in streptozotocin-induced diabetic rats. Pflugers Arch. 2002, 444:446-451.
14. Bassani J.W., Yuan W., Bers D.M. Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am. J. Physiol. 1995, 268:C1313-C1319.
15. Spurgeon H.A., DuBell W.H., Stern M.D., et al. Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J. Physiol. 1992, 447:83-102.
16. Zima A.V., Copello J.A., Blatter L.A. Differential modulation of cardiac and skeletal muscle ryanodine receptors by NADH. FEBS Lett. 2003, 547:32-36.
17. Dunn S.M. Voltage-dependent calcium channels in skeletal muscle transverse tubules. Measurements of calcium efflux in membrane vesicles. J. Biol. Chem. 1989, 264:11053-11060.
18. 2+ transport ATPase by thapsigargin at subnanomolar concentrations. J. Biol. Chem. 1991, 266:13503-13506.
19. 2+ channels. Circ. Res. 1994, 74:271-280.
20. Lopez-Miranda V., Herradon E., Dannert M.T., Alsasua A., Martin M.I. Anandamide vehicles: a comparative study. Eur. J. Pharmacol. 2004, 505:151-161.
21. Danziger R.S., Sakai M., Capogrossi M.C., Spurgeon H.A., Hansford R.G., Lakatta E.G. Ethanol acutely and reversibly suppresses excitation-contraction coupling in cardiac myocytes. Circ. Res. 1991, 68:1660-1668.
22. Delbridge L.M., Connell P.J., Harris P.J., Morgan T.O. Ethanol effects on cardiomyocyte contractility. Clin. Sci. (Lond.) 2000, 98:401-407.
23. Bebarova M., Matejovic P., Pasek M., et al. Effect of ethanol on action potential and ionic membrane currents in rat ventricular myocytes. Acta Physiol. (Oxf.) 2010, 200:301-314.
24. Abadji V., Lin S., Taha G., et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 1994, 37:1889-1893.
25. Kathuria S., Gaetani S., Fegley D., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
26. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. (Lond.) 2006, 30:S13-S18.
27. Shire D., Calandra B., Bouaboula M., et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 1999, 65:627-635.
28. Oz M., Yang K.H., Shippenberg T.S., Renaud L.P., O'Donovan M.J. Cholecystokinin B-type receptors mediate a G-protein-dependent depolarizing action of sulphated cholecystokinin ocatapeptide (CCK-8s) on rodent neonatal spinal ventral horn neurons. J. Neurophysiol. 2007, 98:1108-1114.
29. Baur R., Gertsch J., Sigel E. The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors. Br. J. Pharmacol. 2012, 165:2479-2484.
30. Goodfellow C.E., Glass M. Anandamide receptor signal transduction. Vitam. Horm. 2009, 81:79-110.
31. Zhuang S.Y., Bridges D., Grigorenko E., et al. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 2005, 48:1086-1096.
32. 2+-ATPase by N-arachidonoyl dopamine. Members of the endocannabinoid family as thermogenic drugs. Br. J. Pharmacol. 2012, 166:2060-2069.
33. Antzelevitch C., Sicouri S., Litovsky S.H., et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ. Res. 1991, 69:1427-1449.
34. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol. Ther. 2006, 111:114-144.
35. Ishac E.J., Jiang L., Lake K.D., Varga K., Abood M.E., Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 1996, 118:2023-2028.
36. Oz M., Jaligam V., Galadari S., Petroianu G., Shuba Y.M., Shippenberg T.S. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J. Neurochem. 2010, 112:1454-1464.
37. Epps D.E., Mandel F., Schwartz A. The alteration of rabbit skeletal sarcoplasmic reticulum function by N-acylethanolamine, a lipid associated with myocardial infarction. Cell Calcium 1982, 3:531-543.
38. 2+ in endothelial cells. Br. J. Pharmacol. 1999, 126:1593-1600.
39. Rao G.K., Kaminski N.E. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J. Pharmacol. Exp. Ther. 2006, 317:820-829.
40. 2+ signalling. Cell Calcium 2009, 45:611-624.
41. 2+ release from isolated sarcoplasmic reticulum. Biochem. Pharmacol. 1993, 45:1301-1309.
42. Demuth D.G., Molleman A. Cannabinoid signalling. Life Sci. 2006, 78:549-563.
43. Maslov L.N., Lasukova O.V., Krylatov A.V., Uzhachenko R.V., Pertwee R. Selective cannabinoid receptor agonist HU-210 decreases pump function of isolated perfused heart: role of cAMP and cGMP. Bull. Exp. Biol. Med. 2004, 138:550-553.
44. Li Q., Ma H.J., Zhang H., Qi Z., Guan Y., Zhang Y. Electrophysiological effects of anandamide on rat myocardium. Br. J. Pharmacol. 2009, 158:2022-2029.
45. Krylatov A.V., Maslov L.N., Lasukova O.V., Pertwee R.G. Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart. Bull. Exp. Biol. Med. 2005, 139:558-561.
46. Batkai S., Pacher P., Jarai Z., Wagner J.A., Kunos G. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H595-H600.
47. Patil M., Patwardhan A., Salas M.M., Hargreaves K.M., Akopian A.N. Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons. Neuropharmacology 2011, 61:778-788.
48. Nicholson R.A., Liao C., Zheng J., et al. Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res. 2003, 978:194-204.
49. + currents in rat dorsal root ganglion neurons. Brain Res. 2005, 1062:39-47.
50. Duan Y., Zheng J., Nicholson R.A. Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids. Neurochem. Int. 2008, 52:438-446.
51. 2+ fluxes in rabbit T-tubule membranes. Eur. J. Pharmacol. 2000, 404:13-20.
52. Oz M., Tchugunova Y., Dinc M. Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with fatty acids. Eur. J. Pharmacol. 2004, 502:47-58.
53. Hansen H.S., Moesgaard B., Hansen H.H., Petersen G. N-acylethanolamines and precursor phospholipids-relation to cell injury. Chem. Phys. Lipids 2000, 108:135-150.
54. Berger C., Schmid P.C., Schabitz W.R., Wolf M., Schwab S., Schmid H.H. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?. J. Neurochem. 2004, 88:1159-1167.
55. Epps D.E., Schmid P.C., Natarajan V., Schmid H.H. N-Acylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun. 1979, 90:628-633.
56. Schmid H.H., Berdyshev E.V. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:363-376.
57. Voitychuk O.I., Asmolkova V.S., Gula N.M., et al. Modulation of excitability, membrane currents and survival of cardiac myocytes by N-acylethanolamines. Biochim. Biophys. Acta 2012, 1821:1167-1176.
58. 2+ fluxes in rabbit T-tubule membranes. Arch. Biochem. Biophys. 2005, 434:344-351.
59. Alptekin A., Galadari S., Shuba Y., Petroianu G., Oz M. The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. Eur. J. Pharmacol. 2010, 634:10-15.
60. Oz M., Yang K.H., Dinc M., Shippenberg T.S. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. J. Pharmacol. Exp. Ther. 2007, 323:547-554.
61. Den Ruijter H.M., Berecki G., Opthof T., Verkerk A.O., Zock P.L., Coronel R. Pro- and antiarrhythmic properties of a diet rich in fish oil. Cardiovasc. Res. 2007, 73:316-325.
62. Den Ruijter H.M., Coronel R. The response to fish oil in patients with heart disease depends on the predominant arrhythmia mechanism. Cardiovasc. Drugs Ther. 2009, 23:333-334.
63. 2+ homeostasis of isolated rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1917-H1926.